Satsuma Pharmaceuticals, Inc. Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating expenses
Research and development
General and administrative
Impairment loss
Total operating expenses
Loss from operations
Interest income
Interest expense
Other income (expense), net
Net loss
Unrealized gain (loss) on marketable securities
Comprehensive loss
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted

Loading...

Comments